false
0001922335
0001922335
2025-11-12
2025-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 12, 2025
SYRA
HEALTH CORP.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41822 |
|
85-4027995 |
| (State or other jurisdiction |
|
(Commission |
|
(I. R. S. Employer |
| of incorporation) |
|
File Number) |
|
Identification No.) |
1119
Keystone Way N. #201
Carmel,
IN 46032
(Address
of principal executive offices, including zip code)
(463)
345-8950
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Class A Common Stock, $0.001
par value |
|
SYRA |
|
OTCQB |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Conditions.
On
November 12, 2025, Syra Health Corp. issued a press release announcing its financial results for the third quarter ended September 30,
2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The
information in this report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities
and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall
not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. In addition, the exhibit furnished herewith contain statements intended as
“forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in
such exhibit.
Item
9.01 Financial Statements and Exhibit
(d)
Exhibits.
The
following exhibits are filed with this Current Report on Form 8-K:
Exhibit
Number |
|
Description |
| 99.1 |
|
Press Release dated November 12, 2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the
Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SYRA HEALTH CORP. |
| |
|
|
| Date: November 12, 2025 |
By: |
/s/ Priya
Prasad |
| |
|
Priya
Prasad
Interim
Chief Executive Officer and Chief Financial Officer |
